Skip to main content

Exact Sciences Value Stock - Dividend - Research Selection

Exact sciences

ISIN: US30063P1057 , WKN: 590273

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Columbia Cornerstone Growth Fund Q4 2025 Quarterly Portfolio Recap

2026-03-24
Columbia Cornerstone Growth Fund gained 2.41% in Q4 2025 as market leadership broadened beyond mega-cap tech. Read the full analysis for more details.

Abbott Announces Acquisition Of Exact Sciences To Close March 23rd; Exact Sciences Stockholders To Receive $105/Share

2026-03-20
As previously communicated, this transaction is expected to add approximately $3 billion of incremental sales in 2026, accelerate Abbott's 2026 sales growth by approximately 0.5% and dilute 2026 adjusted earnings per

EXACT SCIENCES CORP (NASDAQ:EXAS) Shows Strong Technical and Fundamental Momentum

2026-03-04
EXACT SCIENCES (EXAS) exemplifies a high-growth momentum stock, meeting strict technical trend rules and showing accelerating earnings and sales fundamentals.

Amalgam Announces Privia Health-Led Colorectal Cancer Screening Program Demonstrates 84% Screening Rates In 2024, Surpassing 80% Goal

2026-03-03
Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia Health (NASDAQ: PRVA)-led colorectal cancer (CRC) screening program,

'Abbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal' - Bloomberg

2026-02-23
https://www.bloomberg.com/news/articles/2026-02-23/abbott-laboratories-kicks-off-bond-sale-for-exact-sciences-deal

Exact Sciences Stockholders Voted To Approve Proposed Acquisition By Abbott

2026-02-20
At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Sciences common stock as of the January 9, 2026 record date

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

2026-02-15

Exact Sciences Earnings Review: Q4 Summary

2026-02-13

Exact Sciences Q4 Adj. EPS $(0.21) Misses $(0.07) Estimate, Sales $878.381M Beat $860.895M Estimate

2026-02-13
Exact Sciences (NASDAQ:EXAS) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.07) by 218.18 percent. This is a 250 percent decrease over losses of $(0.06) per share from

Alger Mid Cap 40 ETF Q4 2025 Portfolio Update

2026-02-12